Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

285 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma.
Long GV, Larkin J, Schadendorf D, Grob JJ, Lao CD, Márquez-Rodas I, Wagstaff J, Lebbé C, Pigozzo J, Robert C, Ascierto PA, Atkinson V, Postow MA, Atkins MB, Sznol M, Callahan MK, Topalian SL, Sosman JA, Kotapati S, Thakkar PK, Ritchings C, Pe Benito M, Re S, Soleymani S, Hodi FS. Long GV, et al. Among authors: sosman ja. J Clin Oncol. 2024 Nov 6:JCO2400400. doi: 10.1200/JCO.24.00400. Online ahead of print. J Clin Oncol. 2024. PMID: 39504507
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab.
Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, Leming PD, Lipson EJ, Puzanov I, Smith DC, Taube JM, Wigginton JM, Kollia GD, Gupta A, Pardoll DM, Sosman JA, Hodi FS. Topalian SL, et al. Among authors: sosman ja. J Clin Oncol. 2023 Feb 10;41(5):943-954. doi: 10.1200/JCO.22.02272. J Clin Oncol. 2023. PMID: 36750016 Clinical Trial.
Nivolumab + Tacrolimus + Prednisone ± Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous Cancers.
Schenk KM, Deutsch JS, Chandra S, Davar D, Eroglu Z, Khushalani NI, Luke JJ, Ott PA, Sosman JA, Aggarwal V, Schollenberger MD, Sharfman WH, Bibee KP, Scott JF, Loss MJ, Wang H, Qi H, Sharon E, Streicher H, Chen HX, Woodward RN, Bagnasco SM, Taube JM, Topalian SL, Brennan DC, Lipson EJ. Schenk KM, et al. Among authors: sosman ja. J Clin Oncol. 2024 Mar 20;42(9):1011-1020. doi: 10.1200/JCO.23.01497. Epub 2024 Jan 22. J Clin Oncol. 2024. PMID: 38252910
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A).
Atkins MB, Jegede OA, Haas NB, Mcdermott DF, Bilen MA, Stein M, Sosman J, Alter R, Plimack ER, Ornstein MC, Hurwitz M, Peace DJ, Einstein D, Catalano PJ, Hammers H, Regan MM. Atkins MB, et al. J Immunother Cancer. 2024 Apr 11;12(4):e008293. doi: 10.1136/jitc-2023-008293. J Immunother Cancer. 2024. PMID: 38604810 Free PMC article. Clinical Trial.
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B).
Atkins MB, Jegede OA, Haas NB, McDermott DF, Bilen MA, Stein M, Sosman JA, Alter R, Plimack ER, Ornstein MC, Hurwitz M, Peace DJ, Signoretti S, Denize T, Cimadamore A, Wu CJ, Braun D, Einstein D, Catalano PJ, Hammers H. Atkins MB, et al. Among authors: sosman ja. J Immunother Cancer. 2023 Mar;11(3):e004780. doi: 10.1136/jitc-2022-004780. J Immunother Cancer. 2023. PMID: 36948504 Free PMC article. Clinical Trial.
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.
Patel SP, Othus M, Chen Y, Wright GP Jr, Yost KJ, Hyngstrom JR, Hu-Lieskovan S, Lao CD, Fecher LA, Truong TG, Eisenstein JL, Chandra S, Sosman JA, Kendra KL, Wu RC, Devoe CE, Deutsch GB, Hegde A, Khalil M, Mangla A, Reese AM, Ross MI, Poklepovic AS, Phan GQ, Onitilo AA, Yasar DG, Powers BC, Doolittle GC, In GK, Kokot N, Gibney GT, Atkins MB, Shaheen M, Warneke JA, Ikeguchi A, Najera JE, Chmielowski B, Crompton JG, Floyd JD, Hsueh E, Margolin KA, Chow WA, Grossmann KF, Dietrich E, Prieto VG, Lowe MC, Buchbinder EI, Kirkwood JM, Korde L, Moon J, Sharon E, Sondak VK, Ribas A. Patel SP, et al. Among authors: sosman ja. N Engl J Med. 2023 Mar 2;388(9):813-823. doi: 10.1056/NEJMoa2211437. N Engl J Med. 2023. PMID: 36856617 Free PMC article. Clinical Trial.
The "Great Debate" at Melanoma Bridge 2022, Naples, December 1st-3rd, 2022.
Ascierto PA, Blank C, Eggermont AM, Garbe C, Gershenwald JE, Hamid O, Hauschild A, Luke JJ, Mehnert JM, Sosman JA, Tawbi HA, Mandalà M, Testori A, Caracò C, Osman I, Puzanov I. Ascierto PA, et al. Among authors: sosman ja. J Transl Med. 2023 Apr 18;21(1):265. doi: 10.1186/s12967-023-04100-y. J Transl Med. 2023. PMID: 37072748 Free PMC article.
Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial.
Motzer RJ, Bex A, Russo P, Tomita Y, Cutuli HJ, Rojas C, Gross-Goupil M, Schinzari G, Melichar B, Barthélémy P, Ruiz Garcia A, Sosman J, Grimm MO, Goh JC, Suarez C, Kollmannsberger CK, Nair SG, Shuch BM, Huang J, Simsek B, Spiridigliozzi J, Lee CW, van Kooten Losio M, Grünwald V. Motzer RJ, et al. J Clin Oncol. 2024 Sep 20:JCO2400773. doi: 10.1200/JCO.24.00773. Online ahead of print. J Clin Oncol. 2024. PMID: 39303200
Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial.
Motzer RJ, Russo P, Grünwald V, Tomita Y, Zurawski B, Parikh O, Buti S, Barthélémy P, Goh JC, Ye D, Lingua A, Lattouf JB, Albigès L, George S, Shuch B, Sosman J, Staehler M, Vázquez Estévez S, Simsek B, Spiridigliozzi J, Chudnovsky A, Bex A. Motzer RJ, et al. Target Oncol. 2023 Sep;18(5):639-641. doi: 10.1007/s11523-023-00987-1. Epub 2023 Sep 2. Target Oncol. 2023. PMID: 37659025 Free PMC article. Clinical Trial.
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma.
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-Del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA. Motzer RJ, et al. Among authors: sosman ja. J Clin Oncol. 2023 Apr 10;41(11):1965-1971. doi: 10.1200/JCO.22.02623. J Clin Oncol. 2023. PMID: 37018919 Clinical Trial.
285 results